BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 16, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Acute myeloid leukemia
Immuno-oncology

Trifunctional NKCE molecule targeting CD123 shows safety and efficacy in preclinical models of AML

Jan. 18, 2023
The alpha chain of the IL-3 receptor, CD123, is frequently overexpressed in acute myeloid leukemia (AML) and is considered an attractive target in the treatment of this disease. However, cytotoxic antibodies or T-cell engagers targeting CD123 have shown insufficient clinical efficacy or safety, confirming the need for alternative targeted approaches.
Read More
Lab research with pipette, microsope
Cancer

Researchers report development of mitotic mislocalizers targeting Aurora kinase B

Jan. 18, 2023
Three Aurora kinases (AURKA, AURKB and AURKC) are required for cell division and their activities/expression is increased in many human cancers. Accordingly, AURK inhibitors have entered early clinical trials, but their approval has been delayed due to off-target dose-limiting toxicity. Inhibition of AURKB catalytic activity is distinguished in that does not depend on disruption of spindle microtubules, but targeting catalytic activity disables both mitotic and nondividing cells.
Read More
Illustration of glucose molecules in a bloodstream
Endocrine/Metabolic

Furan-2-carboxylic acid derivative shows improved anti-gluconeogenesis potency in vivo

Jan. 18, 2023
Researchers from Shanghai Institute of Materia Medica presented the discovery of novel furan-2-carboxylic acid derivatives as potential candidates for the treatment of type 2 diabetes mellitus (T2DM). Synthesis and optimization of SL-010110, a previously identified molecule with the ability to inhibit gluconeogenesis via a unique mechanism, resulted in the discovery of a novel series of derivatives.
Read More
Illustration highlighting the adrenal glands and kidneys
Cancer

Orphagen's OR-449 receives rare pediatric disease designation for pediatric adrenocortical carcinoma

Jan. 18, 2023
The FDA has awarded rare pediatric disease designation to Orphagen Pharmaceuticals Inc.'s OR-449 for the treatment of pediatric adrenocortical carcinoma (ACC). OR-449 is a selective, first-in-class, potent and orally bioavailable small-molecule antagonist to steroidogenic factor-1 (SF-1; NR5A1), an orphan nuclear receptor and transcription factor that is essential for the growth and development of the adrenal gland.
Read More
Intestine
Gastrointestinal

Researchers identify new bacterial species in inflammatory bowel disease

Jan. 18, 2023
Researchers from University Medical Center Utrecht and Yale University School of Medicine have recently described two novel, strictly anaerobic Allobaculum strains, 128T and 539T, isolated from the feces of humans with inflammatory bowel disease (IBD).
Read More
Cancer

Maia nominates lead candidate from telomere-targeting program for cancer

Jan. 18, 2023
Maia Biotechnology Inc. has advanced its telomere-targeting molecule program (Project T3) with the nomination of a lead new molecular entity candidate (MAIA-2021-20) and a back-up new molecular entity candidate (MAIA-2022-12) for progression into preclinical GLP-toxicity and other studies. One of these candidates may then be advanced into clinical trials upon completion of the preclinical evaluations.
Read More
DNA and cancer cells
Diagnostics

Cost-effective techniques for early cancer detection may be a diagnosis gamechanger in low-income countries

Jan. 18, 2023
By Subhasree Nag
Being able to detect cancers early can substantially improve survival, but most early detection tests for cancer rely on expensive and sophisticated molecular techniques that might be difficult to implement in resource strapped environments. Two new studies published last week attempt to overcome this problem.
Read More

Other news to note for Jan. 18, 2023

Jan. 18, 2023
Additional early-stage research and drug discovery news in brief, from: Clearmind Medicine, Kinarus Therapeutics.
Read More
Infection

Debiopharm International presents new antibacterial compounds

Jan. 17, 2023
Debiopharm International SA has identified enoyl-(acyl-carrier protein) reductase FabI (Acinetobacter baumannii) inhibitors reported to be useful for the treatment of bacterial infections and hospital-acquired pneumonia.
Read More
Infection

Shanghai Qilu Pharmaceutical Research and Development Centre synthesizes new compounds for HBV infection

Jan. 17, 2023
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented HBeAg (hepatitis B virus; HBV) and/or HBsAg (HBV) secretion inhibitors reported to be useful for the treatment of HBV infections.
Read More
Previous 1 2 … 1211 1212 1213 1214 1215 1216 1217 1218 1219 … 18070 18071 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing